On April 27, 2020, the inactivated COVID-19 vaccines developed by Sinopharm CNBG's Beijing Institute of Biological Products received clinical trial approval from the National Medical Products Administration.

2020年4月27日,国药集团中国生物北京生物制品研究所研发的新冠灭活疫苗获得国家药监局临床试验批件,为新冠灭活疫苗研发加上双保险。.jpg

Address: Sinopharm Plaza, No 20 Zhichun Road, Haidian district, Beijing

Postcode: 100191

Tel: 86-10-82287727

Fax: 86-10-62033332

Copyright ©  China National Pharmaceutical Group Co Ltd. All rights reserved. Presented by China Daily. 京公网安备 11040102700104号 京ICP备:14023670号-1
On April 27, 2020, the inactivated COVID-19 vaccines developed by Sinopharm CNBG's Beijing Institute of Biological Products received clinical trial approval from the National Medical Products Administration.

2020年4月27日,国药集团中国生物北京生物制品研究所研发的新冠灭活疫苗获得国家药监局临床试验批件,为新冠灭活疫苗研发加上双保险。.jpg

Address: Sinopharm Plaza, No 20 Zhichun Road, Haidian district, Beijing

Postcode: 100191 Tel: 86-10-82287727

Fax: 86-10-62033332

Copyright ©  China National Pharmaceutical Group Co Ltd.
All rights reserved. Presented by China Daily. 京公网安备 11040102700104号
京ICP备:14023670号-1